Chest pain is one of the most common reasons adults in the United States visit the emergency department, leading to more than 7 million patient encounters each year.
Sold as Verquvo, the medication can help patients reduce their risk of cardiovascular death or hospitalization for heart failure.
The study’s authors explored data from more than 28,000 women, focusing on the impact of dozens of biomarkers.
Physicians may want to think twice before prescribing certain medications, including drugs for pain or depression, to some female patients, the authors observed.
Abbott described the update as "critically important," and the American College of Cardiology expressed relief that some proposed changes did not actually end up happening.
The authors examined data from more than 1.2 million patients, tracking individuals who had previously been hospitalized for heart failure and then returned later due to COVID-19.
Researchers compared patient outcomes from 2019 with data from the pandemic’s first four months, sharing their findings in the American Journal of Cardiology.